The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models

Molecular Pharmacology

Volumn 71, Issue 1, 2007, Pages 240-249

  Breedveld, Pauline ^a   Pluim, Dick ^a   Cipriani, Greta ^a   Dahlhaus, Femke ^a   Van Eijndhoven, Maria A J ^a   De Wolf, Cornelia J F ^a   Kuil, Annemieke ^a   Beijnen, Jos H ^a,c   Scheffer, George L ^b   Jansen, Gerrit ^b   Borst, Piet ^a   Schellens, Jan H M ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYMETHOTREXATE; BREAST CANCER RESISTANCE PROTEIN; FOLIC ACID; METHOTREXATE; METHOTREXATE DERIVATIVE; METHOTREXATE DIGLUTAMATE; MITOXANTRONE; RESVERATROL; TOPOTECAN; UNCLASSIFIED DRUG; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG TRANSPORT; IN VITRO STUDY; LEPIDOPTERA; MEMBRANE VESICLE; NONHUMAN; PH; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DOGS; FEMALE; FOLIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; LIVER; METHOTREXATE; MITOXANTRONE; NEOPLASM PROTEINS; RABBITS; STILBENES; TOPOTECAN;

EID: 33845906363     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.028167     Document Type: Article

References (43)

1. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JHM, Koomen G-J, Schinkel AH (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417-425.
2. Altenberg GA, Young G, Horton JK, Glass D, Belli JA, and Reuss L (1993) Changes in intra- or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance. Proc Natl Acad Sci USA 90:9735-9738.
3. Assaraf YG, Babani S, and Goldman ID (1998) Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem 273:8106-8111.
4. Bhatia A, Schafer HJ, and Hrycyna CA (2005) Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers. Biochemistry 44:10893-10904.
5. a values of resorcinol using UV-visible spectroscopy and DFT methods. Spectrochim Acta A Mol Biomol Spectrosc 61:93-102.
6. Boyer MJ and Tannock IF (1992) Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res 52:4441-4447.
7. Breedveld P, Zelcer N, Pluim D, Sönmezer Ö, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, and Schellens JHM (2004) Mechanism of the pharmacokinetic interaction between MTX and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64:5804-5811.
8. Cairnes DA and Evans WE (1983) A simple preparation of the methotrexate metabolites 7-hydroxymethotrexate and 4-deoxy-4-amino-N10-methylpteroic acid. Ther Drug Monit 5:363-366.
9. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, and Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048-4054.
10. Cooray HC, Janvilisri T, van Veen HW, Hladky SB, and Barrand MA (2004) Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 317:269-275.
11. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
12. Gabr A, Kuin A, Aalders M, El-Gawly H, and Smets LA (1997) Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res 57:4811-4816.
13. Gatenby RA and Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-899.
14. Goda K, Balkay L, Marian T, Tron L, Aszalos A, and Szabo G Jr (1996) Intracellular pH does not affect drug extrusion by P-glycoprotein. J Photochem Photobiol B 34:177-182.
15. Greijer AE, de Jong MC, Scheffer GL, Shvarts A, van Diest PJ, and van der Wall E (2005) Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol 27:43-49.
16. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, and Bates SE (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635-6639.
17. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, and Jansen G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532-2535.
18. Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, and Assaraf YG (2004) Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 279:25527-25534.
19. Ishikawa T, Kasamatsu S, Hagiwara Y, Mitomo H, Kato R, and Sumino Y (2003) Expression and functional characterization of human ABC transporter ABCG2 variants in insect cells. Drug Metab Pharmacokinet 18:194-202.
20. Jansen G (1999) Receptor- and carrier-mediated transport systems for folates and antifolates, in Antifolate Drugs in Cancer Therapy (Jackman AL ed) pp 293-321, Humana Press Inc, Totowa, NJ.
21. Kozin SV, Shkarin P, and Gerweck LE (2001) The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res 61:4740-4743.
22. Mahoney BP, Raghunand N, Baggett B, and Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66:1207-1218.
23. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van de Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
24. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, and Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559-4563.
25. Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, and Ishikawa T (2003) A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J 373:767-774.
26. Mizuarai S, Aozasa N, and Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 109:238-246.
27. Moolenaar WH, Tertoolen LG, and de Laat SW (1984) The regulation of cytoplasmic pH in human fibroblasts. J Biol Chem 259:7563-7569.
28. Morisaki K, Robey RW, Özvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, and Bates SE (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56:161-172.
29. Özvegy C, Varadi A, and Sarkadi B (2002) Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. modulation of substrate specificity by a point mutation. J Biol Chem 277:47980-47990.
30. Özvegy-Laczka C, Koblos G, Sarkadi B, and Varadi A (2005a) Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim Biophys Acta 1668:53-63.
31. Özvegy-Laczka C, Varady G, Koblos G, Ujhelly O, Cervenak J, Schuetz JD, Sorrentino BP, Koomen GJ, Varadi A, Nemet K, et al. (2005b) Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface. J Biol Chem 280:4219-4227.
32. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, and Schinkel AH (2005) Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144-152.
33. Poe M (1977) Acidic dissociation constants of folic acid, dihydrofolic acid, and methotrexate. J Biol Chem 252:3724-3728.
34. Rhee MS and Schneider E (2005) Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line. Biochem Pharmacol 69:123-132.
35. Rowland M and Tozer TN (1995). Clinical Pharmacokinetics: Concepts and Applications. Williams & Wilkins, Baltimore.
36. Said HM (2004) Recent advances in carrier-mediated intestinal absorption of watersoluble vitamins. Annu Rev Physiol 66:419-446.
37. Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, and Assaraf YG (2005) ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res 65:8414-8422.
38. Sierra EE, Brigle KE, Spinella MJ, and Goldman ID (1997) pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Further evidence for a third route mediated at low pH. Biochem Pharmacol 53:223-231.
39. Tannock IF and Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49:4373-4384.
40. Underberg WJ, Goossen RM, Smith BR, and Beijnen JH (1990) Equilibrium kinetics of the kew experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 8:681-683.
41. Volk EL and Schneider E (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-5543.
42. Wielinga PR, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, van der Born K, de Haas M, van der Heijden I, Kaspers G, et al. (2005) The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 65:4425-4430.
43. Zhao R, Gao F, Hanscom M, and Goldman ID (2004) A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10:718-727.